Federal Register / Vol. 86, No. 32 / Friday, February 19, 2021 / Notices 10357 

14For example, Respondent testified ‘‘I really 

suffered going through these things—something I 

didn’t do . . . [I] lost most—most of my patients, 

lost a lot of PPO insurances. I have to pay a lot of 

employees, and so many things for something that 

happened—someone faking like, you know, 

accusing you of doing something, but there’s no 100 

percent proof.’’ Tr. 68. 

responsibility. See supra II.C; RD, at 21 

(citing Arvinder Singh, M.D., 81 FR 

8247, 8249–51 (2016)); Stein, 84 FR 

46973. Additionally, Respondent plead 

nolo contendere instead of guilty to the 

charge of offering unlawful Medi-Cal 

remuneration. GX 3. ‘‘In general, 

however, a plea of nolo contendere is 

inconsistent with the acceptance of 

responsibility.’’ RD, at 21 (citing United 

States v. Gordon, 979 F. Supp. 337, 342 

(E.D. Pa. 1997) (internal citations 

omitted)). Finding that a respondent has 

failed to accept responsibility is 

warranted where, as here, the 

respondent pled nolo contendere and 

minimized his role in the crime. See 

Jeffery M. Freesemann, M.D., 76 FR 

60873, 60888 (2011); see also RD, at 22. 

Respondent must convince the 

Administrator that his acceptance of 

responsibility and remorse are 

sufficiently credible to demonstrate that 

the misconduct will not recur. 

Respondent, in his opening statement, 

argued that his testimony would show 

‘‘his genuine remorse . . . .’’ Tr. 14. But 

the record indicates that Respondent 

was not remorseful for what he did; 

instead that he regretted the 

consequences that flowed from his 

conviction.14 Id. at 31, 39, 68. This lack 

of remorse goes hand-in-hand with 

Respondent’s failure to accept 

responsibility and further supports the 

revocation of his registration. 

In sanction determinations, the 

Agency has historically considered its 

interest in deterring similar acts, both 

with respect to the respondent in a 

particular case and the community of 

registrants. See Joseph Gaudio, M.D., 74 

FR 10083, 10095 (2009); Singh, 81 FR at 

8248. In this case, the Respondent knew 

at the time that he committed the crime 

that his actions were illegal—he even 

told Mr. Gonzales that the actions were 

illegal and advised him not to tell 

anyone. Deterring such deceit and 

knowing criminal behavior both in 

Respondent and the general registrant 

community is relevant to ensuring 

compliance with the CSA. Although I 

would not characterize Respondent’s 

underlying crime as particularly 

egregious, Respondent has not 

convinced me that he will not repeat 

such deceitful behavior in using his 

CSA registration. 

Respondent has argued, among other 

things, that he can be entrusted with a 

registration because he has seen over 

15,000 patients in twenty years and has 

never had any issues with prescribing, 

he has never had a malpractice 

complaint, he is very mindful of the 

opioid crisis, and he has satisfied the 

terms of his probation. Tr. 13–14, 37, 74. 

Even assuming, arguendo, all of this to 

be true, Respondent needed to present 

evidence of a credible and persuasive 

acceptance of responsibility. 

Respondent has not. 

Based on Respondent’s failure to 

accept responsibility for his criminal 

misconduct and lack of demonstrated 

remorse, I cannot find that Respondent 

can be entrusted with a DEA 

registration; and therefore, I find that 

revocation is the appropriate sanction 

I will therefore order that 

Respondent’s registration be revoked as 

contained in the Order below. 

Order 

Pursuant to 28 CFR 0.100(b) and the 

authority vested in me by 21 U.S.C. 

824(a), I hereby revoke DEA Certificate 

of Registration No. BA6641472 issued to 

Ibrahim Al-Qawaqneh, D.D.S. This 

Order is effective March 22, 2021. 

D. Christopher Evans, 

Acting Administrator. 

[FR Doc. 2021–03360 Filed 2–18–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–793] 

Importer of Controlled Substances 

Application: VHG Labs DBA LGC 

Standards 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: VHG Labs DBA LGC 

Standards has applied to be registered 

as an importer of basic class(es) of 

controlled substance(s). Refer to 

Supplemental Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before March 22, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

March 22, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on February 2, 2021, VHG 

Labs DBA LGC Standards, 3 Perimeter 

Road, Manchester, New Hampshire 

03103, applied to be registered as an 

importer of the following basic class(es) 

of controlled substance(s): 

Controlled substance Drug code Schedule 

Cathinone ........................................................................................................................................................................ 1235 I 

Methcathinone ................................................................................................................................................................. 1237 I 

Naphyrone ....................................................................................................................................................................... 1258 I 

N-Ethylamphetamine ....................................................................................................................................................... 1475 I 

JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ................................................................................................... 6250 I 

SR-18 (Also known as RCS-–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ............................................... 7008 I 

APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide .............................................................. 7048 I 

JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) ................................................................................................... 7081 I 

SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole ...................................................................... 7104 I 


tkelley on DSKBCP9HB2PROD with NOTICES
10358 Federal Register / Vol. 86, No. 32 / Friday, February 19, 2021 / Notices 

Controlled substance Drug code Schedule 

JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) .............................................................................. 7118 I 

JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ...................................................................................................... 7122 I 

UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .................................................................. 7144 I 

JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ...................................................................................................... 7203 I 

Ibogaine ........................................................................................................................................................................... 7260 I 

Lysergic acid diethylamide .............................................................................................................................................. 7315 I 

Marihuana Extract ........................................................................................................................................................... 7350 I 

Marihuana ........................................................................................................................................................................ 7360 I 

Tetrahydrocannabinols .................................................................................................................................................... 7370 I 

Mescaline ......................................................................................................................................................................... 7381 I 

JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole) ...................................................................................................... 7398 I 

3,4-Methylenedioxymethamphetamine ............................................................................................................................ 7405 I 

5-Methoxy-N–N-dimethyltryptamine ................................................................................................................................ 7431 I 

Psilocyn ........................................................................................................................................................................... 7438 I 

4-Methyl-alphapyrrolidinopropiophenone (4-MePPP) ..................................................................................................... 7498 I 

MDPV (3,4-Methylenedioxypyrovalerone) ....................................................................................................................... 7535 I 

Methylone (3,4-Methylenedioxy-N-methylcathinone) ...................................................................................................... 7540 I 

Butylone ........................................................................................................................................................................... 7541 I 

Pentylone ......................................................................................................................................................................... 7542 I 

Codeine-N-oxide .............................................................................................................................................................. 9053 I 

Desomorphine ................................................................................................................................................................. 9055 I 

Dihydromorphine ............................................................................................................................................................. 9145 I 

Heroin .............................................................................................................................................................................. 9200 I 

Morphine-N-oxide ............................................................................................................................................................ 9307 I 

Normorphine .................................................................................................................................................................... 9313 I 

Tilidine ............................................................................................................................................................................. 9750 I 

Alpha-methylfentanyl ....................................................................................................................................................... 9814 I 

Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ............................................................................... 9821 I 

Methamphetamine ........................................................................................................................................................... 1105 II 

Phenmetrazine ................................................................................................................................................................. 1631 II 

Methylphenidate .............................................................................................................................................................. 1724 II 

Amobarbital ...................................................................................................................................................................... 2125 II 

Pentobarbital .................................................................................................................................................................... 2270 II 

Secobarbital ..................................................................................................................................................................... 2315 II 

Glutethimide ..................................................................................................................................................................... 2550 II 

Phencyclidine ................................................................................................................................................................... 7471 II 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ..................................................................................................................... 8333 II 

Norfentanyl ...................................................................................................................................................................... 8366 II 

Phenylacetone ................................................................................................................................................................. 8501 II 

Codeine ........................................................................................................................................................................... 9050 II 

Dihydrocodeine ................................................................................................................................................................ 9120 II 

Diphenoxylate .................................................................................................................................................................. 9170 II 

Ecgonine .......................................................................................................................................................................... 9180 II 

Ethylmorphine .................................................................................................................................................................. 9190 II 

Hydrocodone ................................................................................................................................................................... 9193 II 

Levorphanol ..................................................................................................................................................................... 9220 II 

Meperidine ....................................................................................................................................................................... 9230 II 

Meperidine intermediate-B .............................................................................................................................................. 9233 II 

Meperidine intermediate-C .............................................................................................................................................. 9234 II 

Methadone intermediate .................................................................................................................................................. 9254 II 

Dextropropoxyphene, bulk (non-dosage forms) .............................................................................................................. 9273 II 

Morphine .......................................................................................................................................................................... 9300 II 

Thebaine .......................................................................................................................................................................... 9333 II 

14-Hydroxmorphone ........................................................................................................................................................ 9665 II 

Noroxymorphone ............................................................................................................................................................. 9668 II 

Sufentanil ......................................................................................................................................................................... 9740 II 

Fentanyl ........................................................................................................................................................................... 9801 II 

The company plans to import the 

listed controlled substances for sale to 

research facilities for drug testing and 

analysis. In reference to drug codes 7360 

(Marihuana) and 7370 

(Tetrahydrocannabinols) the company 

plans to import a synthetic cannabidiol 

and a synthetic tetrahydrocannabinol. 

No other activities for these drug codes 

are authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–03381 Filed 2–18–21; 8:45 am] 

BILLING CODE 4410–09–P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice: (21–009)] 

NASA Astrophysics Advisory 

Committee; Meeting 

AGENCY: National Aeronautics and 

Space Administration. 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, Public 


tkelley on DSKBCP9HB2PROD with NOTICES